MDR-TB Risk Assessment: Identifies patients requiring rapid molecular resistance testing. Drug-susceptibility testing (DST) is gold standard.
Management Recommendation
Standard TB workup recommended. Drug resistance is unlikely but clinical monitoring continues.
Verified
Last Review: 2026-07-17
Last Comprehensive Review: 2026-07-17
Clinical Context
We think this has broad domain relevance to MDR-TB Suspicion & Resistance Risk.
Clinical Context
We think this might be relevant to the clinical guidance for MDR-TB Suspicion & Resistance Risk.
Clinical Context
We think this might be relevant to the clinical guidance for MDR-TB Suspicion & Resistance Risk.
